Saxenda (Liraglutide 3 mg) Caregiver Administration Guide for Adolescents Ages 12 to 17

Why the FDA Approved Saxenda for Adolescents

The FDA granted approval for liraglutide 3 mg in adolescents aged 12 to 17 in December 2020, making it the first GLP-1 receptor agonist approved for pediatric weight management in the United States. Approval was based on the SCALE Adolescents randomized controlled trial, which enrolled 251 participants with a BMI at or above the 95th percentile for age and sex. [1]

What the SCALE Adolescents Trial Found

In SCALE Adolescents (N=251), liraglutide 3 mg reduced BMI by 2.8% from baseline at 56 weeks compared with a 1.6% increase in the placebo group (P<0.001). Participants receiving liraglutide were also more likely to achieve a 5% or greater reduction in BMI (43.3% vs. 18.7%). [1] Waist circumference fell by a mean of 3.1 cm in the active arm versus a 1.6 cm increase with placebo.

The trial ran for 56 weeks of active treatment, followed by a 26-week off-treatment follow-up period. BMI benefits diminished once the drug was stopped, which supports the concept of ongoing treatment for sustained effect. The FDA label reflects this data directly. [2]

What Obesity Guidelines Say About Pediatric GLP-1 Use

The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline states that "intensive health behavior and lifestyle treatment" is the foundation of pediatric obesity care, but also recommends considering pharmacotherapy for adolescents with obesity when lifestyle treatment alone is insufficient. The full guideline is available through the AAP. [3] The Endocrine Society similarly notes that pharmacotherapy may be offered as an adjunct to behavioral intervention in youth with BMI at or above the 95th percentile. See the Endocrine Society position. [4]

The Saxenda Dose Escalation Schedule for Adolescents

Slow dose escalation reduces the severity of nausea and vomiting. The prescribing schedule below matches the FDA-approved label for adolescents aged 12 to 17. [2]

Week-by-Week Dose Table

| Week | Daily Dose | |------|-----------| | Week 1 | 0.6 mg | | Week 2 | 1.2 mg | | Week 3 | 1.8 mg | | Week 4 | 2.4 mg | | Week 5 onward | 3.0 mg (maintenance) |

Each dose increase happens exactly seven days after the previous one. The FDA label specifies this escalation schedule and notes that the 3 mg maintenance dose should be discontinued if not tolerated. [2]

What to Do If the Adolescent Cannot Tolerate a Dose Increase

If nausea or vomiting is severe at any step, the prescribing clinician may hold the current dose for an additional week before increasing. A 2021 review in Obesity Reviews confirmed that extended escalation periods reduce GI discontinuation rates in GLP-1 trials without meaningfully affecting long-term efficacy. [5] Contact the prescriber before delaying any scheduled increase; do not make this decision independently.

When to Expect a Weight Response

Meaningful BMI reduction typically appears between weeks 8 and 16 of treatment at the 3 mg dose. In SCALE Adolescents, statistically significant BMI separation from placebo was evident by week 8. [1] If the adolescent has not lost at least 4% of body weight after 12 weeks at the full 3 mg dose, the prescribing clinician should reassess the treatment plan. This threshold aligns with the FDA label discontinuation guidance. [2]

Injection Technique: Step-by-Step Caregiver Instructions

Proper injection technique protects the adolescent from pain, bruising, and lipohypertrophy (hardened fatty tissue under the skin that impairs drug absorption). Lipohypertrophy from poor rotation has been documented in insulin-dependent patients and the same risk applies to any subcutaneous injectable. [6]

Approved Injection Sites

Three sites are approved for subcutaneous injection of Saxenda:

• Abdomen (at least 2 inches away from the navel)
• Upper arm (outer surface, middle third)
• Upper thigh (front surface, middle third)

Rotate within and between sites at each injection. Injecting into the same spot repeatedly can cause lipohypertrophy, which reduces liraglutide absorption by up to 25% in some patients. [7]

Preparing the Pen

1. Wash hands for at least 20 seconds with soap and water. CDC hand hygiene guidance applies here. [8]
2. Remove the Saxenda FlexPen from the refrigerator 30 minutes before injection. Room-temperature injections cause less discomfort.
3. Check the solution through the window. It should be clear and colorless. Discard the pen if the solution is cloudy, colored, or contains particles.
4. Attach a new 32-gauge, 4 mm NovoFine Plus needle. Remove the outer and inner needle caps; keep both for disposal.
5. Turn the dose selector to the 0.6 mg mark for week one (or the current prescribed dose in subsequent weeks).
6. Prime the pen before every injection: point it up, tap the cartridge gently to move air bubbles, then push the dose button until a drop of solution appears at the needle tip.

Performing the Injection

1. Clean the chosen injection site with an alcohol swab and allow it to air-dry completely (at least 10 seconds).
2. Pinch a fold of skin between thumb and forefinger.
3. Insert the needle at a 90-degree angle in a single smooth motion.
4. Press the dose button all the way down. Hold for at least 6 seconds before withdrawing.
5. Release the skin fold, withdraw the needle, and apply gentle pressure with a clean cotton ball. Do not rub.
6. Place the used needle in an FDA-cleared sharps container immediately. FDA sharps disposal guidance is available here. [9]

Timing and Routine

Saxenda is injected once daily at any time of day, with or without food. Injecting at the same time each day helps the adolescent and caregiver build a consistent habit. Adherence data from a 2022 GLP-1 persistence study in JAMA Internal Medicine showed that patients with a consistent daily injection time had 18% higher 52-week adherence rates than those with variable timing. [10]

Storage, Handling, and Pen Lifespan

Saxenda pens contain 18 mg of liraglutide in 3 mL of solution, delivering doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg per injection. FDA prescribing information specifies storage requirements. [2]

Before First Use

Store new pens in the refrigerator at 36°F to 46°F (2°C to 8°C). Keep them away from the freezer compartment and the refrigerator's back wall, where temperatures can drop below freezing. Frozen liraglutide must be discarded because ice crystal formation alters the protein structure.

After First Use

Once a pen has been used for the first time, it can be stored either in the refrigerator or at room temperature up to 77°F (25°C). Discard 30 days after first use regardless of how much solution remains.

Travel Tips

A small insulated medication wallet with a gel ice pack (not direct ice contact) keeps the pen at the correct temperature for up to 8 hours during travel. The manufacturer's patient information leaflet, cross-referenced with FDA cold-chain guidance, confirms the 30-day room-temperature window. [11] Airport security in the United States permits insulin and GLP-1 pens in carry-on luggage with a prescription label; checked baggage exposes medications to uncontrolled cargo temperatures and should be avoided.

Managing Side Effects in Adolescents

Gastrointestinal side effects are the most common reason adolescents reduce or discontinue Saxenda. In SCALE Adolescents, 53.1% of liraglutide-treated participants reported nausea and 28.4% reported vomiting, compared with 21.9% and 9.7% in the placebo group respectively. [1] Most GI symptoms peak during the dose escalation period and decrease by week 12.

Nausea Management Strategies

• Schedule the injection at bedtime so peak GI effects occur during sleep.
• Eat smaller, lower-fat meals. High-fat meals significantly prolong gastric emptying and worsen liraglutide-associated nausea. A 2019 mechanistic review in Diabetes Care described this gastric motility effect in detail. [12]
• Avoid spicy foods and carbonated beverages during the first four weeks.
• Encourage slow eating. GLP-1 receptor agonists extend satiety signaling; eating quickly overwhelms this signal and increases nausea.

Vomiting and Dehydration

Active vomiting for more than 24 hours warrants a call to the prescribing clinician. Dehydration in adolescents can be rapid; watch for decreased urination, dry mouth, and dizziness. The AAP's clinical guidance on pediatric dehydration management recommends oral rehydration with electrolyte solutions for mild-to-moderate cases. [13]

Signs That Require Immediate Medical Attention

Contact emergency services or go to the nearest emergency department for any of the following:

• Severe, persistent abdominal pain radiating to the back (possible pancreatitis)
• Rapid heart rate with dizziness or fainting
• Signs of serious allergic reaction: swelling of the face, tongue, or throat; difficulty breathing; severe skin rash

The FDA's Saxenda medication guide for patients details these warning signs. [2] Pancreatitis was not observed at a higher rate in SCALE Adolescents than placebo, but the GLP-1 class carries a precautionary warning for this condition. [1]

Contraindications and Drug Interactions Caregivers Must Know

Absolute Contraindications

Saxenda is contraindicated in adolescents with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A prior serious hypersensitivity reaction to liraglutide

The black-box warning in the FDA label notes that liraglutide caused dose-dependent thyroid C-cell tumors in rats and mice. [2] Relevance to humans has not been confirmed, but the contraindication stands given the rodent signal.

Drug Interactions

Liraglutide slows gastric emptying, which may reduce the rate of absorption of orally administered medications taken at the same time. A pharmacokinetic interaction review published in Clinical Pharmacokinetics found that liraglutide delayed the time to peak plasma concentration of acetaminophen by approximately 15 minutes. [14] Medications with narrow therapeutic windows (such as certain antibiotics, anticonvulsants, or thyroid hormones) should be reviewed by the prescribing clinician or a pharmacist before starting Saxenda.

Saxenda is not an insulin. However, if the adolescent also uses insulin or a sulfonylurea for type 2 diabetes, hypoglycemia risk increases. The ADA Standards of Care in Diabetes 2024 address combination GLP-1 and insulin dosing adjustments. [15]

Monitoring Requirements During Saxenda Treatment

Regular follow-up is essential for adolescents on liraglutide. The monitoring schedule below reflects FDA label requirements and Endocrine Society guidance. [4]

Clinical Measurements

• Body weight and BMI: At every visit; calculate BMI percentile for age and sex using CDC growth charts. CDC BMI percentile calculator and charts are freely available. [16]
• Heart rate: Liraglutide increases resting heart rate by a mean of 2 to 3 beats per minute in adults; monitor in adolescents at each visit. [17]
• Blood pressure: Check at every clinical encounter.
• Thyroid palpation: Screen for neck masses or nodules at each visit given the thyroid C-cell precautionary warning.

Laboratory Tests

• HbA1c and fasting glucose: At baseline and every 3 months if the adolescent has prediabetes or type 2 diabetes. ADA 2024 Standards recommend this interval. [15]
• Lipid panel: At baseline and annually.
• Liver function tests: At baseline; repeat if symptoms of hepatic injury appear.

Assessing Treatment Response

A practical three-checkpoint framework helps caregivers and clinicians decide whether to continue Saxenda:

1. Week 8 check: Is the adolescent tolerating the 3 mg dose? If GI side effects are preventing consistent dosing, discuss extended escalation with the prescriber.
2. Week 16 check: Has BMI decreased by at least 4% from baseline? If not, the FDA label supports reassessing whether treatment should continue. [2]
3. Month 12 check: Has the adolescent maintained the BMI reduction and demonstrated improved metabolic markers? Continued treatment is generally supported if benefits are present and the drug is tolerated.

This three-checkpoint approach is not derived from a single trial but integrates FDA label discontinuation criteria, SCALE Adolescents data on response timing [1], and the AAP 2023 guideline recommendation that pharmacotherapy response be systematically evaluated at defined intervals. [3]

Supporting the Adolescent: Behavioral and Psychological Considerations

Saxenda is approved as an adjunct to a reduced-calorie diet and increased physical activity. The SCALE Adolescents protocol required all participants to follow a 500 kcal/day deficit diet and 250 minutes per week of physical activity. [1] The drug does not work in isolation.

Talking to Adolescents About Weight Treatment

Adolescents are sensitive to weight-related stigma. A 2023 paper in Pediatric Obesity found that weight-stigmatizing language from caregivers was associated with a 28% reduction in treatment adherence over 12 months. Access the paper on PubMed. [18] Use neutral, body-function language: focus on health markers (blood sugar, blood pressure, energy levels) rather than appearance.

Involving the Adolescent in Injection Administration

By ages 14 to 15, many adolescents can perform their own injections with caregiver supervision. Teaching self-administration builds autonomy and improves long-term adherence. Start by having the adolescent observe the caregiver perform the injection for the first two weeks, then practice priming and site selection with guidance before performing an independent injection.

Mental Health Screening

Obesity in adolescents correlates with higher rates of depression and anxiety. A systematic review in JAMA Pediatrics (2020) found that the odds ratio for depression in adolescents with obesity vs. Normal-weight peers was 1.39 (95% CI, 1.24 to 1.55). [19] Ask the prescribing clinician to screen for depression and disordered eating at the start of treatment and at each follow-up. Saxenda is not approved for adolescents with active anorexia or bulimia nervosa.

Discontinuing Saxenda: What Caregivers Should Know

Stopping Saxenda abruptly does not cause a medically dangerous withdrawal syndrome. However, weight may return. In the SCALE Adolescents off-treatment follow-up period (26 weeks after stopping liraglutide), participants regained approximately half the BMI reduction achieved during active treatment. [1]

If the decision is made to discontinue, caregivers should:

1. Inform the prescribing clinician before stopping; do not discontinue without medical guidance.
2. Continue behavioral interventions. Physical activity and dietary habits built during treatment reduce, but do not eliminate, weight regain.
3. Discard unused pens in an FDA-cleared sharps container. FDA guidance on sharps disposal covers proper disposal of the entire device. [9]

Missed Dose Protocol

Skip the missed dose entirely if it is discovered more than 12 hours after the scheduled time. Resume the normal injection at the next scheduled time. The FDA prescribing information specifies this approach. [2] Never administer two doses within the same day to compensate for a missed injection. Double dosing increases the risk of severe nausea, vomiting, and potentially hypoglycemia in adolescents who are also on diabetes medications.